Our Work
Latham Advises Intuitive Ventures on Amber Therapeutics’ US$100 Million Series A
June 25, 2024
London team represents investor on funding round of breakthrough med tech company.
Latham & Watkins has advised Intuitive Ventures on its participation in the US$100 million Series A funding round of Amber Therapeutics, a London-based med tech company developing breakthrough adaptive neuromodulation therapy to treat mixed urinary incontinence.
The round was led by New Enterprise Associates, with participation from Intuitive Ventures, F-Prime Capital, and Lightstone Ventures, alongside existing investors Oxford Science Enterprises and 8VC.
The Latham team was led by London corporate partner Shing Lo and Bay Area partner Jim Morrone, with associate Beatrice Leung.